home / stock / pptdf / pptdf news

PPTDF News and Press, PeptiDream Inc

Stock Information
Company Name: PeptiDream Inc
Stock Symbol: PPTDF
Market: OTC
Menu
PPTDF PPTDF Quote PPTDF Short PPTDF News PPTDF Articles PPTDF Message Board
Get PPTDF Alerts

News, Short Squeeze, Breakout and More Instantly...
PPTDF - Radiopharmaceutical market expected to reach ~$14B by 2032

2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...
PPTDF - Alnylam Pharmaceuticals Flying High Despite Limited Near-Term Clinical Catalysts

Alnylam reported second quarter results that included modest outperformance in product revenue, including 12% qoq growth in Onpattro. 2022 should be a big year for the ATTR-CM program, with APOLLO-B results and a possible early look at HELIOS-B. Intellia's NTLA-2001 showed encoura...

PPTDF - Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American Society of Hematology (ASH) Meeting

NEW HAVEN, Conn., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific mo...

PPTDF - Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE(TM)) at The 62nd Annual Society of Hematology (ASH) Meeting

NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific mol...
PPTDF - Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on a Novel Chemical Conjugation Platform (MATE(TM)) at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting

NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, today announced the presentation of proof-of-concept data on KPMW101, an anti-tum...

PPTDF - Kleo Pharmaceuticals Announces Data Presentation on Novel Conjugation Platform at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting

NEW HAVEN, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data from its multi-targeted antibody therapy enha...

PPTDF - Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple Myeloma

NEW HAVEN, Conn., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced today that its lead compound, KP1237, has received Orphan Drug designation from t...
PPTDF - Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients

NEW HAVEN, Conn., July 08, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today that it has received a $5 million grant from...

PPTDF - Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection

NEW HAVEN, Conn. , April 9, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it submitted Pre-IND/IND material to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of vazegepant, an intranasal, high...

PPTDF - Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy

NEW HAVEN, Conn. , March 31, 2020 /PRNewswire/ -- Kleo Pharmaceuticals, Inc. , a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today that it has entered into a research ...
Next 10